DUX4 Antikörper (AA 53-120)

Produktnummer ABIN1713487

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch DUX4 in WB, ELISA, IHC (p), IF (cc), IF (p), ICC und IHC (fro). Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für DUX4 Antikörper (AA 53-120) (ABIN1713487)

Target: DUX4 (Double Homeobox 4 (DUX4))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser DUX4 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))

Produktdetails anti-DUX4 Antikörper

Bindungsspezifität: AA 53-120

Homologie: Human

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human DUX4

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu DUX4

Target: DUX4 (Double Homeobox 4 (DUX4))

Andere Bezeichnung: DUX4

Hintergrund:

Synonyms: Double homeobox protein 10, Double homeobox protein 4, Double homeobox protein 4/10, DUX10, DUX4_HUMAN.

Background: DUX4 is a homeodomain protein with a similar protein sequence to Pax3 and Pax7. Defects in DUX4 may be the cause of facioscapulohumeral muscular dystrophy (FSHD). FSHD is characterized by weakness of the muscles of the face, upper-arm and shoulder girdle. Severity is highly variable. Weakness is slowly progressive and about 20 % of affected individuals eventually require a wheelchair. Approximately 70-90 % of individuals have inherited the disease-causing deletion from a parent, and approximately 10-30 % of affected individuals have FSHD as the result of a de novo deletion. Offsprings of an affected individual have a 50 % chance of inheriting the deletion.